Literature DB >> 35086616

The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there.

C Lange1, A Kay2, A M Mandalakas3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35086616      PMCID： PMC9296677          DOI： 10.5588/ijtld.21.0736

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   3.427


× No keyword cloud information.
  17 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  PREVENTIVE TREATMENT IN TUBERCULOSIS: A STATEMENT BY THE COMMITTEE ON THERAPY, AMERICAN THORACIC SOCIETY.

Authors:  E H RUNYON
Journal:  Am Rev Respir Dis       Date:  1965-02

3.  Implementation of isoniazid preventive therapy in children aged under 5 years exposed to tuberculosis in Benin.

Authors:  M Adjobimey; E Masserey; C Adjonou; G Gbénagnon; V Schwoebel; S Anagonou; J-P Zellweger
Journal:  Int J Tuberc Lung Dis       Date:  2016-08       Impact factor: 2.373

4.  Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Authors:  Dick Menzies; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Heejin Kim; Joseph Obeng Baah; Guy B Marks; Richard Long; Vernon Hoeppner; Kevin Elwood; Hamdan Al-Jahdali; Martin Gninafon; Lika Apriani; Raspati C Koesoemadinata; Afranio Kritski; Valeria Rolla; Boubacar Bah; Alioune Camara; Isaac Boakye; Victoria J Cook; Hazel Goldberg; Chantal Valiquette; Karen Hornby; Marie-Josée Dion; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

5.  Safety and Side Effects of Rifampin versus Isoniazid in Children.

Authors:  Thierno Diallo; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Joseph Obeng Baah; Guy B Marks; Richard Long; Kevin Elwood; David Zielinski; Martin Gninafon; Diah A Wulandari; Lika Apriani; Chantal Valiquette; Federica Fregonese; Karen Hornby; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti; Dick Menzies
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

6.  Preventive therapy of tuberculous infection.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1974-09

7.  One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.

Authors:  Susan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A Jean Juste; Javier R Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V Fletcher; Eric Nuermberger; Richard E Chaisson
Journal:  N Engl J Med       Date:  2019-03-14       Impact factor: 91.245

8.  The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.

Authors:  Nikos P Spyridis; Panayotis G Spyridis; Anna Gelesme; Vana Sypsa; Mina Valianatou; Flora Metsou; Dimitris Gourgiotis; Maria N Tsolia
Journal:  Clin Infect Dis       Date:  2007-08-06       Impact factor: 9.079

9.  American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1986-08

Review 10.  100 years of Mycobacterium bovis bacille Calmette-Guérin.

Authors:  Christoph Lange; Peter Aaby; Marcel A Behr; Peter R Donald; Stefan H E Kaufmann; Mihai G Netea; Anna M Mandalakas
Journal:  Lancet Infect Dis       Date:  2021-09-07       Impact factor: 25.071
View more
  1 in total

1.  Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.

Authors:  Lorenzo Guglielmetti; Gunar Günther; Claude Leu; Daniela Cirillo; Raquel Duarte; Alberto L Garcia-Basteiro; Delia Goletti; Mateja Jankovic; Liga Kuksa; Florian P Maurer; Frédéric Méchaï; Simon Tiberi; Frank van Leth; Nicolas Veziris; Christoph Lange
Journal:  Eur Respir J       Date:  2022-05-19       Impact factor: 33.795
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.